Aizawa, Hitoshi http://orcid.org/0000-0002-5395-695X
Kato, Haruhisa
Oba, Koji
Kawahara, Takuya
Okubo, Yoshihiko
Saito, Tomoko
Naito, Makiko
Urushitani, Makoto
Tamaoka, Akira
Nakamagoe, Kiyotaka
Ishii, Kazuhiro
Kanda, Takashi
Katsuno, Masahisa
Atsuta, Naoki
Maeda, Yasushi
Nagai, Makiko
Nishiyama, Kazutoshi
Ishiura, Hiroyuki
Toda, Tatsushi
Kawata, Akihiro
Abe, Koji
Yabe, Ichiro
Takahashi-Iwata, Ikuko
Sasaki, Hidenao
Warita, Hitoshi
Aoki, Masashi
Sobue, Gen
Mizusawa, Hidehiro
Matsuyama, Yutaka
Haga, Tomohiro
Kwak, Shin
Funding for this research was provided by:
Japan Agency for Medical Research and Development (CCT-B-2804)
Article History
Received: 13 March 2021
Revised: 17 June 2021
Accepted: 17 June 2021
First Online: 30 June 2021
Declarations
:
: K.O. reports receiving honoraria from Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Eisai Co., Ltd, Chugai Pharmaceutical Co, Ltd., and Daiichi Sankyo Co., Ltd., outside the submitted work. M.K. reports receiving grants from AMED, Japan, during the conduct of the study; receiving grants from Mitsubishi Tanabe Pharma, grants from Sanofi, and consulting fees from Eisai, outside the submitted work. N.A. reports receiving grants from the Center for Clinical Trials, Japan Medical Association, during the conduct of the study. H.I. reports receiving speaker fees from Eisai, outside the submitted work. M.A. reports receiving research grants for Research on Nervous and Mental Disorders, Research on Rare and Intractable Diseases, Research on Psychiatric and Neurological Diseases and Mental Health from the Japanese Ministry of Health Labor and Welfare; Grants-in-Aid for Scientific Research, an Intramural Research Grant for Neurological Psychiatric Disorders from National Center of Neurology and Psychiatry (NCNP); Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); and a grants of Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED); and funding for travel and speaker honoraria from Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd, Sanofi K.K. Novartis Pharma K.K and Dainippon Sumitomo Pharma Co. Ltd. H.M. reports receiving grants from the Japan Agency for Medical Research and Development and grants from the Japanese Ministry of Health, Labor and Welfare, outside the submitted work. The other authors have nothing to report.
: This study was performed in accordance with the International Conference on Harmonization Good Clinical Practices Consolidated Guideline. The study protocol was approved by an independent ethics committee or Institutional Review Board according to local regulations at each site. Written informed consent was obtained from all patients before initiating study procedures.